BRISBANE,Daniel Welch, the chief executive officer who led the sale of Triangle Pharmaceuticals, is the new CEO of InterMune, Inc. He replaces William Ringo, who remains chairman of the board.
InterMune (Nasdaq: ITMN) is a biopharmaceutical firm.
Welch holds an MBA from the University of North Carolina.
